Role of PARP Inhibition in Recurrent Ovarian Cancer

Video

Recent Videos
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content
The safety profile of pembrolizumab in the KEYNOTE-B96 study was comparable with prior reports of the agent, and investigators observed no new safety signals.

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Russ Conroy
May 15th 2025
Article

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers

Russ Conroy
April 30th 2025
Article

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Tim Cortese
March 26th 2025
Article

The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

Russ Conroy
March 19th 2025
Article

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.